Back to Search Start Over

CENTRAL AND PERIPHERAL INVOLVEMENT OF THE RETINA IN THE INITIAL STAGES OF DIABETIC RETINOPATHY.

Authors :
Santos AR
Almeida AC
Rocha AC
Reste-Ferreira D
Marques IP
Cunha-Vaz Martinho A
Mendes L
Santos T
Lewis W
Cunha-Vaz J
Source :
Retina (Philadelphia, Pa.) [Retina] 2024 Apr 01; Vol. 44 (4), pp. 700-706.
Publication Year :
2024

Abstract

Purpose: To determine the degree of central microvascular closure using optical coherence tomography angiography in eyes of patients with type 2 diabetes with visible lesions only in the central retina or only in the periphery.<br />Methods: Cross-sectional study. All 127 eyes underwent ultra-widefield fundus photography 200° examinations with OPTOS California (Optos, Dunfermline, United Kingdom) and Cirrus Angioplex optical coherence tomography angiography 3 × 3 mm acquisitions (ZEISS, Dublin, CA).<br />Results: Twenty-five eyes showed visible lesions only in the central retina, 57 only in the peripheral retina, and 45 presented visible lesions in entire retina. The group with visible lesions only in the periphery showed definite closure in the superficial capillary plexus in 49% of the eyes, whereas the group with visible lesions only in the central seven-early treatment diabetic retinopathy study fields area showed a definite closure in 64%.<br />Conclusion: Central capillary closure is already present in the initial stages of diabetic retinopathy even when lesions are only visible in the peripheral retina. Capillary closure in the superficial capillary plexus is three times more frequent than in the deep capillary plexus, demonstrating earlier closure of the superficial capillary plexus. Eyes with visible lesions only in the periphery show a milder form of retinopathy.<br />Competing Interests: A.R. Santos, A.C. Almeida, A.C. Rocha, D. Reste-Ferreira, I.P. Marques, A. Cunha-Vaz Martinho, L. Mendes and T. Santos declare no conflicts of interest. W. Lewis is a consultant/contractor for Carl Zeiss Meditec. J. Cunha-Vaz reports grants from Bayer, Boehringer Ingelheim, and Carl Zeiss Meditec and is a consultant for Alimera Sciences, Bayer, Boehringer Ingelheim, Carl Zeiss Meditec, and Roche.<br /> (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.)

Details

Language :
English
ISSN :
1539-2864
Volume :
44
Issue :
4
Database :
MEDLINE
Journal :
Retina (Philadelphia, Pa.)
Publication Type :
Academic Journal
Accession number :
38109709
Full Text :
https://doi.org/10.1097/IAE.0000000000004021